Untitled Document
[an error occurred while processing this directive]
www.expresspharmaonline.com FORTNIGHTLY INSIGHT FOR PHARMA PROFESSIONALS
16 - 31 March 2012  
Untitled Document
Sections

Market
Management
Research
Pharma Ally
Pharma Life

Specials

Express Biotech

Services
Editorial Advisory Board
Open Forum
Subscribe/Renew
Archives
Search
Media Kit
Contact Us
Network Sites
Express Computer
Express Channel Business
Express Hospitality
Express TravelWorld
Express Healthcare
Group Sites
ExpressIndia
Indian Express
Financial Express

[an error occurred while processing this directive]

[an error occurred while processing this directive]

[an error occurred while processing this directive]
Home - Market - Article

Zota Healthcare applies for patent in pain management

Usha Sharma - Mumbai

The Rs 50-crore Surat-based pharmaceutical company Zota Healthcare which has already applied for a patent on RTFIT, it liver fitness formulation, has applied for another patent, this time for a oral formulation of paracetamol, which claims can cure high grade fever via oral doses and injection as well.

Talking about the new innovation and patent filing, Dr Sanjay Agrawal, Medical Consultant, Zota Healthcare said, “After intensive research over the last three years, we have developed a new product for pain management. This unique and novel formulation will help to reduce pain in a more advanced manner. These innovations are in the final stages and will be soon introduced in the Indian market.”

Agrawal further said that their research resulted in a superior formulation of paracetamol, which is more soluble, stable, bioavailable and is pleasantly tasting. Further, with this technology, the parenteral form will be less viscous, more stable with reduced chances of precipitation during storage and processing and is easily administrable even at higher concentrations of paracetamol with lesser chances of thrombus formation, claims Agarwal.

Paracetamol is an antipyretic that can reduce fever by affecting the part of the brain known as the hypothalamus, which regulates the temperature of the body. This is why paracetamol is included in many cough, cold and flu medications. It is sparingly soluble drug with bitter taste and requires around half an hour to start its action after oral administration. Further, the low solubility in conventional injectable form can cause a viscous solution and thrombus formation at the site of intravenous injection. Without these limitations, paracetamol can be a better drug with a difference. Hence Zota believes the process innovation is patentable.

Meanwhile, work on the existing product in the market, RTFIT, continues. Citing clinical trials results, Agrawal highlighted, “RTFIT has undergone many pre-and post-launch clinical trials and all the trials have proven the unmatched benefits for patients suffering from alcoholic liver diseases, hepatitis, toxic liver diseases and so on. The overwhelming response for RTFIT from all corners has paved the way for many such further innovations.”

Speaking about company's plans for an IPO and corporate strategy going forward, Ketan Zota, Managing Director, Zota Healthcare said, “We are in the process of hiring an agency who will look after all IPO filing related activities and we are hopeful that by early next year we shall be able to file the Draft Red Herring Prospectus (DRHP). Recently, we have commissioned our new plant at Surat SEZ and with the help of this new plant, we are targeting a turnover of Rs 80 crore, up from the current Rs 50 crore, in financial year 2011-12. We are also aiming to achieve over Rs 100 crore turnover by 2013.”

Zota Healthcare has a manpower strength of 225 and plans to increase its headcount by 50 per cent each year. The company is in the process of applying to WHO – Geneva, and TGA – Australia for approvals. Once it receives these approvals, it will apply for US FDA approval.

u.sharma@expressindia.com

 



FEEDBACK: We would love to hear from you -- what you like about our content, what you dont, and even how you think we can improve. Please send your feedback to: editorial.ep@expressindia.com


Copyright 2001: The Indian Express Limited. All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of The Indian Express Limited. Site managed by BPD.